{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:24:32Z","timestamp":1791815072515,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jconrel.2026.114771","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:29:44Z","timestamp":1772497784000},"page":"114771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Extracellular vesicles from IL-18-overexpressing and\/or TGF-\u03b21-deprived tumor cells as an immunogenic antigen source for next-generation DC vaccines"],"prefix":"10.1016","volume":"393","author":[{"given":"Joanna","family":"Rossowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Nawrocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Szermer-Olearnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalina","family":"P\u0119cherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Waer-Asea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Karpi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Tracz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Milczarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114771_bb0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114771_bb0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2026.114771_bb0015","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114771_bb0020","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2026.114771_bb0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/85438","article-title":"Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming","volume":"7","author":"Wolfers","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114771_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-021-01376-w","article-title":"The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells","volume":"20","author":"Hosseini","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.114771_bb0035","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.24249","article-title":"Induction of myeloid-derived suppressor cells by tumor exosomes","volume":"124","author":"Xiang","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114771_bb0040","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1158\/0008-5472.CAN-06-1819","article-title":"Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-\u03b2\u2013mediated suppressive activity on T lymphocytes","volume":"66","author":"Valenti","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114771_bb0045","doi-asserted-by":"crossref","first-page":"27033","DOI":"10.18632\/oncotarget.7041","article-title":"Colorectal cancer cell-derived extracellular vesicles induce phenotypic alteration of T cells into tumor-growth supporting cells with transforming growth factor-\u03b21-mediated suppression","volume":"7","author":"Yamada","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.114771_bb0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000484677","article-title":"Enhancement of anti-leukemia immunity by leukemia\u2013derived exosomes via downregulation of TGF-\u03b21 expression","volume":"44","author":"Huang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2026.114771_bb0055","doi-asserted-by":"crossref","first-page":"6978","DOI":"10.1039\/D0BM01385D","article-title":"Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation","volume":"8","author":"Li","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2026.114771_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00211","article-title":"Antitumor potential of extracellular vesicles released by genetically modified murine colon carcinoma cells with overexpression of interleukin-12 and shRNA for TGF-\u03b21","volume":"10","author":"Rossowska","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0065","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.cgt.7700964","article-title":"IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro","volume":"13","author":"Vujanovic","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114771_bb0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cellimm.2004.02.002","article-title":"Induction of dendritic cell maturation by IL-18","volume":"227","author":"Li","year":"2004","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1074-7613(00)80614-7","article-title":"IL-12 acts directly on DC to promote nuclear localization of NF-\u03baB and primes DC for IL-12 production","volume":"9","author":"Grohmann","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.114771_bb0080","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00109-006-0102-0","article-title":"Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells","volume":"84","author":"Dai","year":"2006","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114771_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14712\/fb2004050010007","article-title":"Loss of tumorigenicity of murine colon carcinoma MC38\/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes","volume":"50","author":"Pajtasz-Piasecka","year":"2004","journal-title":"Folia Biol (Praha)."},{"key":"10.1016\/j.jconrel.2026.114771_bb0090","first-page":"1539","article-title":"Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo","volume":"21","author":"Rossowska","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2026.114771_bb0095","first-page":"1539","article-title":"Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo","volume":"21","author":"Rossowska","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2026.114771_bb0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fimmu.2017.00713","article-title":"Intratumoral lentivector-mediated TGF-\u03b21 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and dendritic cells","volume":"8","author":"Rossowska","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0248-4900(93)90259-H","article-title":"Characterization of membrane sugar-specific receptors in cultured high endothelial cells from mouse peripheral lymph nodes","volume":"79","author":"Bizouarne","year":"1993","journal-title":"Biol. Cell."},{"key":"10.1016\/j.jconrel.2026.114771_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0163-7258(00)00086-3","article-title":"Basis for effective combination cancer chemotherapy with antimetabolites","volume":"87","author":"Peters","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.114771_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1471-2407-13-294","article-title":"Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model","volume":"13","author":"Milczarek","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.114771_bb0120","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jmb.2015.09.019","article-title":"ExoCarta: a web-based compendium of exosomal cargo","volume":"428","author":"Keerthikumar","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pro.4218","article-title":"PANTHER: making genome-scale phylogenetics accessible to all","volume":"31","author":"Thomas","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2026.114771_bb0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41590-021-00899-0","article-title":"Extracellular vesicles in immunomodulation and tumor progression","volume":"22","author":"Marar","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3858\/emm.2011.43.5.029","article-title":"Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects","volume":"43","author":"Lee","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114771_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biomaterials.2016.09.031","article-title":"Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA","volume":"111","author":"Morishita","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114771_bb0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00432-006-0184-7","article-title":"Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells","volume":"133","author":"Yang","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.04.012","article-title":"Modulation of immune responses in lentiviral vector-mediated gene transfer","volume":"342","author":"Annoni","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2026.114771_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1169","article-title":"Enhancing the efficacy of immunotherapy using radiotherapy","volume":"9","author":"Keam","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cellimm.2004.02.002","article-title":"Induction of dendritic cell maturation by IL-18","volume":"227","author":"Li","year":"2004","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4049\/jimmunol.164.1.64","article-title":"Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-\u03b3 production by dendritic cells","volume":"164","author":"Fukao","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.114771_bb0175","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00109-006-0102-0","article-title":"Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells","volume":"84","author":"Dai","year":"2006","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.jconrel.2026.114771_bb0180","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s12026-017-8944-9","article-title":"The role of TGF-beta signaling in dendritic cell tolerance","volume":"65","author":"Esebanmen","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.114771_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474318","article-title":"Low-dose cyclophosphamide depletes circulating na\u00efve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy","volume":"7","author":"Noordam","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.114771_bb0190","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","article-title":"Tumor cell lysates as immunogenic sources for cancer vaccine design","volume":"10","author":"Gonz\u00e1lez","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2026.114771_bb0195","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3892\/mmr.2014.2606","article-title":"Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes","volume":"10","author":"Dong","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2026.114771_bb0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines: the promise and limitations in clinical trials","volume":"10","author":"Srivatsan","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2026.114771_bb0205","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1535-7163.MCT-20-0484","article-title":"Exosome surface display of IL12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared with recombinant IL12","volume":"20","author":"Lewis","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.114771_bb0210","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","article-title":"Recent advances in extracellular vesicles for therapeutic cargo delivery","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114771_bb0215","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.18632\/oncotarget.20812","article-title":"Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.114771_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13102497","article-title":"Dendritic cell-derived exosomes: next generation of cancer immunotherapy","volume":"13","author":"Dhar","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.114771_bb0225","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114771_bb0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-021-01490-9","article-title":"Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma","volume":"21","author":"Serrat\u00ec","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.114771_bb0235","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-2478(03)00128-7","article-title":"MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells","volume":"89","author":"Utsugi-Kobukai","year":"2003","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jconrel.2026.114771_bb0240","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12031-015-0506-9","article-title":"Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice","volume":"56","author":"Bu","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2026.114771_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1071008","article-title":"Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC","volume":"5","author":"Besse","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.114771_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2026.114771_bb0255","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8238459","article-title":"How supraphysiological oxygen levels in standard cell culture affect oxygen-consuming reactions","volume":"2018","author":"Stuart","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.jconrel.2026.114771_bb0260","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114771_bb0265","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/cells12172147","article-title":"Dendritic cell vaccines: a shift from conventional approach to new generations","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.114771_bb0270","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00262-013-1407-9","article-title":"Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma","volume":"62","author":"Ghansah","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.114771_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105309","article-title":"Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview","volume":"164","author":"Calmeiro","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2026.114771_bb0280","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:58:59Z","timestamp":1781715539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":56,"alternative-id":["S0168365926001732"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114771","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracellular vesicles from IL-18-overexpressing and\/or TGF-\u03b21-deprived tumor cells as an immunogenic antigen source for next-generation DC vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114771"}}